•
Dec 31, 2020
CryoPort Q4 2020 Earnings Report
CryoPort reported record results for Q4 2020, marked by strategic acquisitions and strong performance in the cell and gene therapy market.
Key Takeaways
Cryoport's Q4 2020 was a transformational quarter with strong performance and continued momentum, especially in Cell and Gene Therapy. The acquisitions of MVE Biological Solutions and CRYOPDP expanded the company's global platform and capabilities. The company reported 36% organic growth in the fourth quarter.
Increased regenerative medicine clinical trials supported to 528, compared to 436 at the end of 2019.
Closed acquisitions of MVE Biological Solutions and CRYOPDP, expanding global platform.
Established first jointly operated global logistics center in Osaka, Japan with CRYOPDP.
Launched ESG program, marking first disclosure of ESG information.
CryoPort
CryoPort
CryoPort Revenue by Segment
Forward Guidance
Cryoport anticipates that 2021 will be another excellent year for the company.